Fluticasone furoate is a highly potent and selective glucocorticoid receptor (GR) agonist (EC50 = 57 pM by A549-based GRE reporter assay; IC50 = 29 nM against 3.2 ng/mL TNF-α-induced NF-κB activation by A549 reporter line; 117 pM against 1 ng/mL LPS-induced TNF-α release from human PBMCs). Fluticasone furoate prevents ovalbumin-induced lung eosinophilia in an allergic lung inflammation model in vivo (30 μg/brown Norway rat intratracheally) with much reduced or no potency toward mineralocorticoid, progesterone, androgen or estrogen receptors.